191 related articles for article (PubMed ID: 30535450)
1. MicroRNA‑29a enhances cisplatin sensitivity in non‑small cell lung cancer through the regulation of REV3L.
Chen X; Zhu H; Ye W; Cui Y; Chen M
Mol Med Rep; 2019 Feb; 19(2):831-840. PubMed ID: 30535450
[TBL] [Abstract][Full Text] [Related]
2. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer.
Pang J; Ye L; Zhao D; Zhao D; Chen Q
Cell Biol Int; 2020 Dec; 44(12):2416-2426. PubMed ID: 32808744
[TBL] [Abstract][Full Text] [Related]
3. miRNA‑328 overexpression confers cisplatin resistance in non‑small cell lung cancer via targeting of PTEN.
Wang C; Wang S; Ma F; Zhang W
Mol Med Rep; 2018 Nov; 18(5):4563-4570. PubMed ID: 30221716
[TBL] [Abstract][Full Text] [Related]
4. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells.
Wang W; Sheng W; Yu C; Cao J; Zhou J; Wu J; Zhang H; Zhang S
Oncol Rep; 2015 Sep; 34(3):1460-8. PubMed ID: 26165320
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
[TBL] [Abstract][Full Text] [Related]
6. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
Qi MM; Ge F; Chen XJ; Tang C; Ma J
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
[TBL] [Abstract][Full Text] [Related]
7. miR‑139‑5p enhances cisplatin sensitivity in non‑small cell lung cancer cells by inhibiting cell proliferation and promoting apoptosis via the targeting of Homeobox protein Hox‑B2.
Du H; Bao Y; Liu C; Zhong A; Niu Y; Tang X
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33300085
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
9. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
10. Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p.
Luo S; Shen M; Chen H; Li W; Chen C
Mol Med Rep; 2020 Nov; 22(5):3822-3832. PubMed ID: 32901838
[TBL] [Abstract][Full Text] [Related]
11. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
Huang RS; Zheng YL; Zhao J; Chun X
Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
[TBL] [Abstract][Full Text] [Related]
12. RAD52 motif‑containing protein 1 promotes non‑small cell lung cancer cell proliferation and survival via cell cycle regulation.
Xu G; Du J; Wang F; Zhang F; Hu R; Sun D; Shen J
Oncol Rep; 2018 Aug; 40(2):833-840. PubMed ID: 29845285
[TBL] [Abstract][Full Text] [Related]
13. Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.
Agulló-Ortuño MT; García-Ruiz I; Díaz-García CV; Enguita AB; Pardo-Marqués V; Prieto-García E; Ponce S; Iglesias L; Zugazagoitia J; López-Martín JA; Paz-Ares L; Nuñez JA
Cancer Chemother Pharmacol; 2020 Mar; 85(3):525-535. PubMed ID: 31832811
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
15. miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells.
Lin C; Xie L; Lu Y; Hu Z; Chang J
Int J Mol Med; 2018 Apr; 41(4):2050-2058. PubMed ID: 29328427
[TBL] [Abstract][Full Text] [Related]
16. REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells.
Yang L; Shi T; Liu F; Ren C; Wang Z; Li Y; Tu X; Yang G; Cheng X
PLoS One; 2015; 10(3):e0120334. PubMed ID: 25781640
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
18. REV3L, the catalytic subunit of DNA polymerase ζ, is involved in the progression and chemoresistance of esophageal squamous cell carcinoma.
Zhu X; Zou S; Zhou J; Zhu H; Zhang S; Shang Z; Ding WQ; Wu J; Chen Y
Oncol Rep; 2016 Mar; 35(3):1664-70. PubMed ID: 26752104
[TBL] [Abstract][Full Text] [Related]
19. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA‑608 sensitizes non‑small cell lung cancer cells to cisplatin by targeting TEAD2.
Wang Y; Li F; Ma D; Gao Y; Li R; Gao Y
Mol Med Rep; 2019 Oct; 20(4):3519-3526. PubMed ID: 31485614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
